Lately, other formulations have been developed in order to improve engagers’ efficacy, namely BiKES that redirect NK cells against myeloma cells through CD16A and tumor-specific antigens, tumor-targeted immunomodulators that target both co-stimulatory molecules and tumor antigens, and dual immunomodulators that target either inhibitory and/or activation markers simultaneously [106]. Here, FCGR3A is linked to plasma cell myeloma.